as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹210.42
Change
+2.15 (1.03%)
Open
₹208.1
Prev. Close
₹208.27
Day High
₹213.4
Day Low
₹205.96
Volume Analysis
Traded
35,178
Delivered
17,334
Delivery %
49.28%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (16.4%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹221.34 | ₹217.37 | ₹213.9 | ₹209.93 | ₹206.46 | ₹202.49 | ₹199.02 |
| Fibonacci | ₹217.37 | ₹214.53 | ₹212.77 | ₹209.93 | ₹207.09 | ₹205.33 | ₹202.49 |
| Camarilla | ₹212.47 | ₹211.78 | ₹211.1 | ₹209.93 | ₹209.74 | ₹209.06 | ₹208.37 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+9.29%
1 Week
-2.91%
1 Month
-3.44%
3 Months
-11.04%
6 Months
+0.24%
1 Year
+2.23%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹72.57
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.68%
Net margin 14.98% × asset turnover 0.91x × equity multiplier 1.15x
Company Overview
Sector
Healthcare
Market Cap
₹1,402 Cr
Book Value
₹36.4
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Jagsonpal Pharmaceuticals holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (28/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%). Strong 3-year EPS growth (16.4%).
TopFund Score — Fundamentals Quality
68/100 — GoodData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −Stock is trading at 5.82 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M
Audio recording of Jagsonpal Pharmaceuticals’ Q2 FY27 earnings conference call uploaded on website.
Newspaper Publication providing extracts of Unaudited Results of Company for the quarter and half ended September 30, 2026.
Press Release for Unaudited Financial Results for the quarter September 30, 2026
Jagsonpal reported Q2FY27 revenue of ₹964 million, H1 PAT up 10.3%, plus acquisition updates.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 | 96 |
| Expenses + | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 | 79 |
| Operating Profit | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 | 17 |
| OPM % | 14.0% | 7.0% | 6.0% | 17.0% | 22.0% | 21.0% | 15.0% | 19.0% | 22.0% | 22.0% | 17.0% | 21.0% | 18.0% |
| Other Income + | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 | 16 |
| Tax % | 25.0% | 25.0% | 22.0% | 25.0% | 25.0% | 17.0% | 24.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| Net Profit + | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 | 12 |
| EPS in Rs | 1 | 1 | 1 | 1 | 2 | 5 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -4 | -21 | -22 | 2 | 29 | 57 | 35 | 23 | 0 | -1 | 10 | 9 | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 |
| Expenses + | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 229 |
| Operating Profit | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 58 |
| OPM % | 6.0% | 8.0% | 4.0% | -9.0% | 6.0% | 5.0% | 10.0% | 12.0% | 14.0% | 11.0% | 19.0% | 20.0% |
| Other Income + | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 10 |
| Interest | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit before tax | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 58 |
| Tax % | 30.0% | 20.0% | 18.0% | -1.0% | 20.0% | 16.0% | 22.0% | 29.0% | 23.0% | 25.0% | 21.0% | 25.0% |
| Net Profit + | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 43 |
| EPS in Rs | 0 | 1 | 2 | -2 | 1 | 1 | 3 | 3 | 4 | 3 | 8 | 6 |
| Dividend Payout % | 22.0% | 8.0% | 2.0% | -2.0% | 9.0% | 17.0% | 15.0% | 56.0% | 49.0% | 59.0% | 30.0% | 62.0% |
| Sales growth | -4 | 4 | 0 | -12 | 32 | -5 | 19 | 16 | 9 | -12 | 29 | 7 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 263 | 227 |
| Borrowings + | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 8 | 9 |
| Other Liabilities + | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 32 | 68 |
| Total Liabilities | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 | 318 |
| Fixed Assets + | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 85 | 105 |
| CWIP | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 | 0 |
| Other Assets + | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 231 | 213 |
| Total Assets | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 | 318 |
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | 9 | -3 | -2 | 31 | 11 | 28 | 7 | 47 | 35 | 55 | 47 |
| Cash from Investing Activity + | 0 | -2 | 41 | -3 | -1 | -11 | -2 | -26 | -58 | -25 | -45 | -36 |
| Cash from Financing Activity + | -1 | -6 | -34 | -1 | -6 | -1 | -7 | -18 | 0 | -9 | -12 | -12 |
| Net Cash Flow | 2 | 1 | 5 | -6 | 24 | 0 | 19 | -36 | -11 | 2 | -2 | -1 |
| Free Cash Flow | 4 | 6 | 40 | -5 | 30 | 12 | 28 | 6 | 48 | 35 | 90 | 47 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 53 | 83 | -6 | 14 | 311 | 150 | 164 | 54 | 158 | 189 | 124 | 101 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 30.16% | 30.33% | 30.01% | 29.63% | 30.1% | 30.11% | 30.12% | 30.25% | 30.34% | 29.44% | 28.04% | 27.4% |
| Promoters | 68.48% | 68.09% | 68.04% | 67.98% | 67.82% | 67.77% | 67.65% | 67.54% | 67.39% | 67.89% | 69.06% | 68.82% |
| FII | 0.53% | 0.73% | 1.1% | 2.3% | 2.1% | 2.1% | 2.17% | 2.12% | 2.12% | 2.44% | 2.3% | 2.13% |
| DII | 0.82% | 0.84% | 0.84% | 0.11% | 0.0% | 0.0% | 0.05% | 0.08% | 0.15% | 0.22% | 0.62% | 1.64% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Jagsonpal Pharmaceuticals (this stock) | 1,402 | — | 5.82 | — |
| Fermenta Biotech Ltd. | 1,367 | 29.4 | 3.27 | 17.3% |
| Anlon Healthcare Limited | 1,348 | 37.8 | 5.25 | 18.4% |
| Amrutajan Health Ltd | 1,461 | 71.7 | 13.58 | 20.0% |
| Shalby Limited | 1,317 | 33.6 | 1.29 | 2.45% |
| Bharat Parenterals Ltd. | 1,522 | 1227.0 | 4.59 | -2.54% |
| Kopran Ltd | 1,281 | 32.6 | 2.44 | 4.91% |
Which Mutual Funds Hold Jagsonpal Pharmaceuticals?
Frequently Asked Questions about Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals (JAGSNPHARM) closed at ₹210.42 on NSE on 19 November 2026, up 2.15 (1.03%) from the previous close.
Jagsonpal Pharmaceuticals trades on the NSE (National Stock Exchange of India) under the symbol JAGSNPHARM.
Jagsonpal Pharmaceuticals has a dividend yield of 1.89%.
Jagsonpal Pharmaceuticals's 52-week high is ₹265.0 and its 52-week low is ₹155.0.
Jagsonpal Pharmaceuticals has a market capitalisation of ₹1,402 crore.
Jagsonpal Pharmaceuticals has a TopFund Quality Score of 68/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Jagsonpal Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.